Monroe facility ramp-up delays
Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
GLENMARK / Q3-FY24 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. respiratory launch timeline uncertainty
Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.
India business recovery may be slower than guided
Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.